CAJ | 학술논문

目的：探讨复发转移乳腺癌联合化疗后继续卡培他滨节拍化疗维持治疗的疗效及安全性。方法对64例复发转移性乳腺癌患者，6～8周期联合化疗后疗效评价无疾病进展，根据治疗方法不同分为节拍化疗组、常规化疗组和对照组。节拍化疗组23例给予小剂量卡培他滨节拍化疗500 g、2次／日，持续口服；常规化疗组21例给予卡培他滨1250 mg／（m 2?次）、2次／日，连续14 d，休7 d，21 d 为1周期；对照组20例未予特殊治疗。4周期后观察疗效及毒副反应。结果疗效方面，客观缓解率节拍化疗组13．0％，常规化疗组19．0％，（P＜0．05），肿瘤控制率节拍化疗组82．6％，常规化疗组85．7％，（P＞0．05）；毒副反应方面，节拍化疗组 III ～IV 度骨髓抑制、消化道反应、手足综合征发生率均低于常规化疗组。结论卡培他滨维持治疗能使晚期复发转移性乳腺癌患者临床受益，小剂量节拍式维持治疗与常规剂量维持治疗控瘤效果相当，且毒副反应低、可耐受。
목적：탐토복발전이유선암연합화료후계속잡배타빈절박화료유지치료적료효급안전성。방법대64례복발전이성유선암환자，6～8주기연합화료후료효평개무질병진전，근거치료방법불동분위절박화료조、상규화료조화대조조。절박화료조23례급여소제량잡배타빈절박화료500 g、2차／일，지속구복；상규화료조21례급여잡배타빈1250 mg／（m 2?차）、2차／일，련속14 d，휴7 d，21 d 위1주기；대조조20례미여특수치료。4주기후관찰료효급독부반응。결과료효방면，객관완해솔절박화료조13．0％，상규화료조19．0％，（P＜0．05），종류공제솔절박화료조82．6％，상규화료조85．7％，（P＞0．05）；독부반응방면，절박화료조 III ～IV 도골수억제、소화도반응、수족종합정발생솔균저우상규화료조。결론잡배타빈유지치료능사만기복발전이성유선암환자림상수익，소제량절박식유지치료여상규제량유지치료공류효과상당，차독부반응저、가내수。
Objective To evaluate the efficacy and safety of capecitabine metronomic chemotherapy as the maintenance therapy in the treatment of metastatic breast cancer (MBC).Methods 64 cases were selected for the study, who had recurrent metastatic breast cancer (MBC) and received 6 to 8 cycles of combination chemotherapy without disease progression, and they were randomly di-vided into metronomic chemotherapy group, conventional chemotherapy group and control group.For the metronomic chemotherapy group (n=23), patients were continuously given capecitabine 500mg twice daily.The conventional chemotherapy group (n=21) first received capecitabine 1250 mg/m 2 twice a day for 14 days, and then took a break for 7 days.The treatment cycle was 21 days.For the control group (n=20), no treatment was given.Efficacy and toxicity were observed after 4 cycles of treatment.Result The response rate in metronomic chemotherapy group was 13.0% and that in the conventional chemotherapy group was 19.0%.The disease control rate in metronomic chemotherapy group was 82.6% and in conventional chemotherapy group was 85.7%, (P>0.05).As for toxicity reaction, the metronomic chemotherapy group was lower than the conventional chemotherapy group in the myelosuppression rate of Grade III ~IV, gastroenteric reaction and hand-foot syndrome.Conclusion Capecitabine metronomic chemotherapy, with its clini-cal efficacy comparable to conventional chemotherapy and better tolerance and fewer adverse reactions, is applicable for the treatment of metastatic breast cancer as maintenance treatment.